CUDC-427 is an antagonist of second-generation pan-selective IAP used for the treatment of various cancers.

GDC-0917 (0.1 nM-10 μM) induces the reduction of cIAP1 levels in PBMCs in a concentration-dependent manner. It showing greater than 80% inhibition at concentrations greater than 0.1 μM (56.5 ng/mL).

GDC-0917 is well tolerated, with all dose groups experiencing a<11% decrease in mean body weight. GDC-0917 (0.08-16.3 mg/kg) shows antitumor activity in a dose-dependent manner in the MDA-MB-231-X1.1 Breast Cancer Xenograft. GDC-0917 has low to moderate clearance in the mouse (12.0 mL/min/kg), rat (27.0 mL/min/kg), and dog (15.3 mL/min/kg), and high clearance in the monkey (67.6 mL/min/kg).

1446182-94-0

C29H36N6O4S

564.7

GDC-0917

DMSO:100 mg/mL (177.09 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years